PMID- 38388874
OWN - NLM
STAT- MEDLINE
DCOM- 20240401
LR  - 20240401
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 84
IP  - 2
DP  - 2024 Feb
TI  - Tirzepatide: A Review in Type 2 Diabetes.
PG  - 227-238
LID - 10.1007/s40265-023-01992-4 [doi]
AB  - Tirzepatide (Mounjaro((R))), a first-in-class dual incretin agonist of the 
      glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 
      (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to 
      improve glycaemic control in adults with type 2 diabetes mellitus (T2DM) in the 
      USA, EU, Japan and other countries. It comes as single-dose prefilled pens and 
      single-dose vials. In phase III SURPASS trials, once-weekly subcutaneous 
      tirzepatide, as monotherapy or add-on-therapy to oral glucose-lowering 
      medications and insulin, was superior to the GLP-1 receptor agonists (RAs) 
      dulaglutide 0.75 mg and semaglutide 1 mg as well as basal and prandial insulin 
      for glycaemic control and weight loss in adults with inadequately controlled 
      T2DM. Tirzepatide was generally well tolerated, with a safety profile consistent 
      with that of GLP-1 RAs. Tirzepatide was associated with a low risk of clinically 
      significant or severe hypoglycaemia and no increased risk of major adverse 
      cardiovascular events. Adverse events were mostly mild to moderate in severity, 
      with the most common being gastrointestinal events including nausea, diarrhoea, 
      decreased appetite and vomiting. In conclusion, tirzepatide is a valuable 
      addition to the treatment options for T2DM.
CI  - (c) 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - France, Nicole L
AU  - France NL
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Syed, Yahiya Y
AU  - Syed YY
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240223
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - OYN3CCI6QE (tirzepatide)
RN  - 0 (Insulin)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - IY9XDZ35W2 (Glucose)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Glucagon-Like Peptide-2 Receptor)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Insulin
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Glucose
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Glucagon-Like Peptide-2 Receptor
MH  - *Gastric Inhibitory Polypeptide
OAB - Many people with type 2 diabetes mellitus (T2DM) do not achieve and maintain 
      glycaemic and weight management goals using currently available treatments. 
      Tirzepatide (Mounjaro((R))) is the first incretin-based glucose-lowering medication 
      to be approved as an add-on to diet and exercise in adults with T2DM that targets 
      both the glucose-dependent insulinotropic polypeptide receptor (GIP) and the 
      glucagon-like peptide-1 (GLP-1) receptor. In patients with inadequately 
      controlled T2DM, tirzepatide improved glycaemic control and body weight more so 
      than dulaglutide 0.75 mg, semaglutide 1 mg and insulin when used on its own or in 
      combination with other medications. Tirzepatide was generally well tolerated and 
      had a low risk of hypoglycaemia. The most common adverse events were usually 
      short-lived gastrointestinal-related events, which were generally mild to 
      moderate in nature, including nausea, diarrhoea, decreased appetite and vomiting. 
      Tirzepatide is a valuable addition to the treatment options for people with 
      inadequately controlled T2DM.
OABL- eng
EDAT- 2024/02/23 00:42
MHDA- 2024/04/01 06:42
CRDT- 2024/02/22 23:58
PHST- 2023/12/20 00:00 [accepted]
PHST- 2024/04/01 06:42 [medline]
PHST- 2024/02/23 00:42 [pubmed]
PHST- 2024/02/22 23:58 [entrez]
AID - 10.1007/s40265-023-01992-4 [pii]
AID - 10.1007/s40265-023-01992-4 [doi]
PST - ppublish
SO  - Drugs. 2024 Feb;84(2):227-238. doi: 10.1007/s40265-023-01992-4. Epub 2024 Feb 23.